Integer Holdings Corp (ITGR) stock intrinsic value fair value estimate & owner earnings analysis

Integer Holdings is the leading outsourced manufacturer of components and finished devices for cardiac, vascular and neuromodulation implants, plus a smaller book of other medical and non-medical work. It builds parts - batteries, leads, catheters, electronic subassemblies - that go inside pacemakers, neurostimulators, structural-heart devices and vascular tools sold under the brands of large device makers. Once a device using an Integer part is FDA-approved, switching suppliers means re-validating the whole device, which is what gives these customer relationships their durability. The business runs as three product lines. Cardio & Vascular is now about 60% of sales and the growth engine, up 17% in 2025 on new electrophysiology and neurovascular product ramps plus a handful of bolt-on acquisitions (even excluding those acquisitions, the segment's organic growth was still north of 10%). Cardiac Rhythm Management & Neuromodulation is about 36% of sales and growing only modestly, because a legacy spinal-cord-stimulation program the company flagged as winding down back in 2020 has now largely rolled off. Other Markets is the smallest piece at about 4% of sales and shrinking quickly - Integer announced in 2022 that it was deliberately exiting its Portable Medical battery business over several years, and that planned exit is most of why this segment fell 27% in 2025 and should keep shrinking toward zero over the next couple of years. Owner earnings - cash generated from the business after stripping out working-capital swings, stock-based compensation, and the portion of capital spending used to grow rather than simply maintain operations - have run from about $4.55 per diluted share in 2019 to $3.30 in the pandemic-affected 2020, back up into the $3-4 range through 2021-2024 (a period that also included a step-up in capital spending to build new Cardio & Vascular manufacturing capacity), and then to $5.89 in 2025 (about $4.58 excluding a one-time non-cash charge tied to this year's convertible-debt refinancing). We used the median of the last seven years, $3.88 per share, as the normalized starting point rather than the strong 2025 figure, since 2025 benefited from an unusual mix of acquired revenue and a large non-cash refinancing item unlikely to repeat. Three cases, each a continuous story rather than a percentage of another: Bear case, about $67 per share: one of Integer's three largest customers - together nearly half of 2025 sales - meaningfully cuts or in-sources a program, something that has already happened twice in disclosed form (the 2020 neuromodulation wind-down and the 2022 Portable Medical exit). Growth turns modestly negative for a couple of years before settling near 1% annually, while roughly $1.2 billion of debt (convertible notes plus a credit facility, costing about $27 million of interest in 2026) continues to be serviced from a smaller cash-flow base. Base case, about $147 per share: Cardio & Vascular keeps compounding at a high-single to low-double-digit rate for several years, Cardiac Rhythm Management & Neuromodulation grows at a market rate of low-single digits, and the Portable Medical exit finishes running off by around 2027. Growth decelerates gradually toward roughly 4% annually by the back half of a ten-year forecast, and we assume the business's long, demonstrated record of quality-controlled manufacturing for regulated medical devices supports modest continued growth (2.5% a year) after that, reflecting the switching-cost relationship with customers rather than any specific new contract. Bull case, about $227 per share: the current wave of new-product ramps in electrophysiology and neurovascular devices continues for longer and at a faster pace, the legacy CRM&N headwind is fully behind the company, and bolt-on acquisitions keep adding to Cardio & Vascular at roughly the pace seen in 2025 - all things Integer has already shown it can do, not a hoped-for change in the story. What could make this wrong: customer concentration is real and increasing - the single largest customer grew from 16% to 20% of sales over the last three years - so one customer's decision could move results more than at a typical peer. The company also took on real leverage this year through two rounds of convertible-note financing, adding fixed interest costs ahead of any return to shareholders. On the other side, if Cardio & Vascular's current growth simply continues, the base case could prove conservative. The margin-of-safety price near $79 reflects a wide margin of safety against the bear case, given how concentrated the growth is in a handful of customers and product launches and given the debt load. It also assumes no disclosed loss of business from any of the three largest customers.